$CERS

Jayaraman Vivek K sold $125K of CERS

Jayaraman Vivek K (Chief Operating Officer) sold 42,359 shares of CERUS CORP (CERS) at $2.94 ($0.12M total) on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jayaraman Vivek K
Published Jul 2, 2026, 11:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CERS
Neutral
medium confidence
Mentioned
$CERS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CERSNeutralLow
01

Why it matters

The newest fact is the COO’s open-market sale details (shares, price, total value) and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

This provides a fresh, auditable datapoint on insider selling activity, but it is not a fundamental catalyst.

03

What to watch

Insider sales can still matter if they cluster with other insider selling or coincide with deteriorating fundamentals; this brief contains only one transaction and no context on prior activity.

Relevance 3/10Novelty 5/10Timing: new SEC Form 4 filed after-hours on 2026-07-02

Background

The article is an SEC Form 4 insider transaction disclosure for Cerus Corp (CERS).

Company-level read

Ticker impact

$CERSNeutralMedium confidence
Context

Cerus COO Jayaraman Vivek K filed a Form 4 selling 42,359 shares at $2.9429 on 2026-06-30 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact would be short-lived and sentiment-driven.

Evidence & confidence

The filing is a disclosed insider transaction (not an earnings/guidance or operational catalyst). It is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider liquidity disclosure.

None.

None.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations; traders may ignore it unless paired with other negative catalysts.

Key entities

  • CERUS CORP

    Company whose insider transaction was disclosed on SEC Form 4.

  • Jayaraman Vivek K

    Chief Operating Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CERSMed

Cerus Q3 Earnings Call Highlights

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

$CERSMed

Cerus: Q3 Earnings Snapshot

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.

$CERSMedAI 8/10

Cerus' blood-safety system meets main goal in late-stage trial

Cerus Corp reported that its Intercept blood-safety technology met the main goal in a late-stage trial, showing treated red blood cells performed as well as conventional ones in transfusions. The study found no significant difference in adverse events, though some patients developed temporary antibodies. The technology is not yet FDA-approved.

$CERSMed

Cerus Corporation Announces Third Quarter 2026 Financial Results

CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl

MedAI 8/10

Treated red blood cells performed no worse than conventional cells on hemoglobin gains in Cerus’ Phase 3 trial.

Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.